계절 인플루엔자의 항바이러스제 사용 지침

키워드

참고문헌 (90)

1. Mandell GL., "Principles and practice of infectious disease. 7th ed" (2009), Churchill Livingstone
2. Public Health Weekly Report, "Korean Center for Disease Control and Prevention", 581~600 (2012)
3. InfluenzaSentinel Surveillance Report, "Korean Center for Disease Control and Prevention", 1~ (2012)
4. "WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses" (2010)[URL]
5. Brankston G., "Transmission of influenza A in human beings", Lancet Infect Dis, 7, pp.257~265 (2007)
6. Cox NJ., "Influenza", Lancet, 354, pp.1277~1282 (1999)
7. Carrat F., "Time lines of infection and disease in human influenza : a review of volunteer challenge studies", Am J Epidemiol, 167, pp.775~785 (2008)
8. Hayden FG., "Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense", J Clin Invest, 101, pp.643~649 (1998)
9. Hall CB., "Nosocomial influenza infection as a cause of intercurrent fevers in infants", Pediatrics, 55, pp.673~677 (1975)
10. Nicholson KG., "Clinical features of influenza", Semin Respir Infect, 7, pp.26~37 (1992)
11. Thompson WW., "Influenza-associated hospitalizations in the United States", JAMA, 292, pp.1333~1340 (2004)
12. Fiore AE., "Prevention and Control of Influenza : Recommendations of the Advisory Committee on Immunization Practices(ACIP), 2008", MMWR Recomm Rep, 57, pp.1~60 (2008)
13. Ho YC., "Prognostic factors for fatal adult influenza pneumonia", J Infect, 58, pp.439~445 (2009)
14. Bautista E., "Clinical aspects of pandemic 2009 influenza A(H1N1)virus infection", N Engl J Med, 362, pp.1708~1719 (2010)
15. Schrag SJ., "Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in children : 2003-2004", Pediatr Infect Dis J, 25, pp.395~400 (2006)
16. Maricich SM., "Neurologic complications associated with influenza A in children during the 2003-2004 influenza season in Houston, Texas", Pediatrics, 114, pp.e626~e633 (2004)
17. Abe M., "Clinical study of influenza-associated rhabdomyolysis with acute renal failure", Clin Nephrol, 66, pp.166~170 (2006)
18. Mamas MA., "Cardiovascular manifestations associated with influenza virus infection", Int J Cardiol, 130, pp.304~309 (2008)
19. Guarner J., "Histopathologic and immunohistochemical features of fatal influenza virus infection in children during the 2003-2004 season", Clin Infect Dis, 43, pp.132~140 (2006)
20. Harper SA., "Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management : clinical practice guidelines of the Infectious Diseases Society of America", Clin Infect Dis, 48, pp.1003~1032 (2009)
21. Storch GA., "Rapid diagnostic tests for influenza", Curr Opin Pediatr, 15, pp.77~84 (2003)
22. Grijalva CG., "Accuracy and interpretation of rapid influenza tests in children", Pediatrics, 119, pp.e6~e11 (2007)
23. Uyeki TM., "Low sensitivity of rapid diagnostic test for influenza", Clin Infect Dis, 48, pp.e89~e92 (2009)
24. Hurt AC., "Performance of six influenza rapid tests in detecting human influenza in clinical specimens", J Clin Virol, 39, pp.132~135 (2007)
25. Schmid ML., "Prospective comparative study of culture specimens and methods in diagnosing influenza in adults", BMJ, 316, pp.275~ (1998)
26. Uyeki TM., "Influenza diagnosis and treatment in children : a review of studies on clinically useful tests and antiviral treatment for influenza", Pediatr Infect Dis J, 22, pp.164~177 (2003)
27. Sung RY., "Comparative study of nasopharyngeal aspirate and nasal swab specimens for diagnosis of acute viral respiratory infection", J Clin Microbiol, 46, pp.3073~3076 (2008)
28. Jefferson T, "Amantadine and rimantadine for influenza A in adults", Cochrane Database Syst Rev, pp.CD001169~ (2006)
29. Bright RA., "Incidence of adamantane resistance among influenza A(H3N2)viruses isolated worldwide from 1994 to 2005 : a cause for concern", Lancet, 366, pp.1175~1181 (2005)
30. Bright RA., "Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States", JAMA, 295, pp.891~894 (2006)
31. Hayden FG., "Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group", N Engl J Med, 337, pp.874~880 (1997)
32. Treanor JJ., "Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza : a randomized controlled trial. US Oral Neuraminidase Study Group", JAMA, 283, pp.1016~1024 (2000)
33. Whitley RJ., "Oral oseltamivir treatment of influenza in children", Pediatr Infect Dis J, 20, pp.127~133 (2001)
34. de Bruijn IA., "Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination", J Infect Dis, 179, pp.31~36 (1999)
35. Hedrick JA., "Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age : a randomized controlled trial", Pediatr Infect Dis J, 19, pp.410~417 (2000)
36. Lalezari J., "Zanamivir for the treatment of influenza A and B infection in high-risk patients : a pooled analysis of randomized controlled trials", Arch Intern Med, 161, pp.212~217 (2001)
37. Monto AS., "Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis", J Antimicrob Chemother, 44(Suppl B), pp.23~29 (1999)
38. Kaiser L., "Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations", Arch Intern Med, 163, pp.1667~1672 (2003)
39. Johnston SL., "Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma", Pediatr Infect Dis J, 24, pp.225~232 (2005)
40. 정희진, "Phase III Randomized, Double-Blind Study Comparing Single-Dose Intravenous Peramivir with Oral Oseltamivir in Patients with Seasonal Influenza Virus Infection", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(11), pp.5267~5276, AMER SOC MICROBIOLOGY
41. Won Suk Choi, "The Clinical Usefulness of the SD Bioline Influenza Antigen Test^® for Detecting the 2009 Influenza A (H1N1) Virus", Yonsei Medical Journal, 52(4), pp.683~685 (2011), 연세대학교의과대학
42. Louie JK., "Rapid influenza antigen test for diagnosis of pandemic(H1N1)2009", Emerg Infect Dis, 16, pp.824~826 (2010)
43. Blyth CC., "Rapid-test sensitivity for novel swine-origin influenza A(H1N1)virus in humans", N Engl J Med, 361, pp.2493~ (2009)
44. Vasoo S., "Rapid antigen tests for diagnosis of pandemic(Swine)influenza A", H1N1, 2009, pp.49, 1090~1093
45. Fiore AE., "Antiviral agents for the treatment and chemoprophylaxis of influenza : Recommendations of the Advisory Committee on Immunization Practices(ACIP)", MMWR Recomm Rep, 60, pp.1~24 (2011)
46. American Academy of Pediatrics Committee on Infectious Diseases, "Recommendations for prevention and control of influenza in children", Pediatrics, 128, pp.813~825 (2012)
47. "NICE technology appraisal guidance 168 Amantadine, oseltamivir and zanamivir for the treatment of influenza" (2009)[URL]
48. Allen UD., "The use of antiviral drugs for influenza : recommended guidelines for practitioners", Can J Infect Dis Med Microbiol, 17, pp.273~284 (2006)
49. Wutzler P., "Antiviral treatment and prophylaxis of influenza in primary care : German recommendations", J Clin Virol, 31, pp.84~91 (2004)
50. Thompson WW., "Mortality associated with influenza and respiratory syncytial virus in the United States", JAMA, 289, pp.179~186 (2003)
51. Dodds L., "Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women", CMAJ, 176, pp.463~468 (2007)
52. Callaghan WM., "Deaths from seasonal influenza among pregnant women in the United States, 1998-2005", Obstet Gynecol, 115, pp.919~923 (2010)
53. Siston AM., "Pandemic 2009 influenza A(H1N1)virus illness among pregnant women in the United States", JAMA, 303, pp.1517~1525 (2010)
54. Creanga AA., "Severity of 2009 pandemic influenza A(H1N1)virus infection in pregnant women", Obstet Gynecol, 115, pp.717~726 (2010)
55. Jamieson DJ., "H1N1 2009 influenza virus infection during pregnancy in the USA", Lancet, 374, pp.451~458 (2009)
56. Jain S., "Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009", N Engl J Med, 361, pp.1935~1944 (2009)
57. Louie JK., "Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1)infection in California", JAMA, 302, pp.1896~1902 (2009)
58. Morgan OW., "Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1)disease. PLoS", PLoS One, 5, pp.e9694~ (2010)
59. Jefferson T., "Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children", Cochrane Database Syst Rev, 1, pp.CD008965~ (2012)
60. Dutkowski R., "Safety and pharmacokinetics of oseltamivir at standard and high dosages", Int J Antimicrob Agents, 35, pp.461~467 (2010)
61. Wattanagoon Y., "Pharmacokinetics of high-dose oseltamivir in healthy volunteers", Antimicrob Agents Chemother, 53, pp.945~952 (2009)
62. Kohno S., "Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients", Antimicrob Agents Chemother, 55, pp.2803~2812 (2011)
63. Duval X., "Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebocontrolled trial", PLoS Med, 7, pp.e1000362~ (2010)
64. Kim WY., "Triple-Combination Antiviral Drug for Pandemic H1N1 Influenza Virus Infection in Critically Ill Patients on Mechanical Ventilation", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(12), pp.5703~5709 (2011), AMER SOC MICROBIOLOGY
65. Nguyen JT., "Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro", PLoS One, 5, pp.e9332~ (2010)
66. Hoopes JD., "Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus", PLoS One, 6, pp.e29778~ (2012)
67. Nguyen JT., "Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses", PLoS One, 7, pp.e31006~ (2012)
68. Smee DF., "Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A(H1N1)and B viruses", Antivir Chem Chemother, 17, pp.185~192 (2006)
69. Ilyushina NA., "Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice", Antivir Ther, 12, pp.363~370 (2007)
70. Smee DF., "Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A(H5N1)virus infections in cell culture and in mice", Antimicrob Agents Chemother, 53, pp.2120~2128 (2009)
71. Centers for Disease Control and Prevention, "Oseltamivirresistant 2009 pandemic influenza A(H1N1)virus infection in two summer campers receiving prophylaxis--North Carolina, 2009", MMWR Morb Mortal Wkly Rep, 58, pp.969~972 (2009)
72. Greer LG., "Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications", Obstet Gynecol, 115, pp.711~716 (2010)
73. Donner B., "Safety of oseltamivir in pregnancy : a review of preclinical and clinical data", Drug Saf, 33, pp.631~642 (2010)
74. Rasmussen SA., "Pandemic influenza and pregnant women", Emerg Infect Dis, 14, pp.95~100 (2008)
75. Hartert TV., "Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season", Am J Obstet Gynecol, 189, pp.1705~1712 (2003)
76. "KFDA approval of Tamiflu"[URL]
77. Anonymous., "New concerns about oseltamivir", Lancet, 369, pp.1056~ (2007)
78. Blumentals WA., "The safety of oseltamivir in patients with influenza : analysis of healthcare claims data from six influenza seasons", Med Gen Med, 9, pp.23~ (2007)
79. Toovey S., "Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir : a comprehensive review", Drug Saf, 31, pp.1097~1114 (2008)
80. He G., "Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802", Clin Pharmacokinet, 37, pp.471~484 (1999)
81. "KFDA approval of Relenza"[URL]
82. Anonymous., "The periodic health examination. Canadian Task Force on the Periodic Health Examination", Can Med Assoc J, 121, pp.1193~1254 (1979)
83. Hayden FG., "Antiviral management of seasonal and pandemic influenza", J Infect Dis, 194(Suppl 2), pp.S119~S126 (2006)
84. "WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses" (2010)[URL]
85. Hayden FG., "Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group", N Engl J Med, 343, pp.1282~1289 (2000)
86. Monto AS., "Zanamivir prophylaxis : an effective strategy for the prevention of influenza types A and B within households", J Infect Dis, 186, pp.1582~1588 (2002)
87. Hayden FG., "Management of influenza in households : a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis", J Infect Dis, 189, pp.440~449 (2004)
88. Welliver R., "Effectiveness of oseltamivir in preventing influenza in household contacts : a randomized controlled trial", JAMA, 285, pp.748~754 (2001)
89. Lan Y., "Adamantane resistance among influenza A(H3N2)viruses isolated from the mainland of China", Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 20, pp.21~23 (2006)
90. Kaiser L., "Short-term treatment with zanamivir to prevent influenza : results of a placebo-controlled study", Clin Infect Dis, 30, pp.587~589 (2000)

관련 논문AI추천